Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study
Hemalatha G. Rangarajan(Nationwide Children's Hospital), Allistair Abraham(Children's National), Jennifer Krajewski, Angela Smith, Tami John(Baylor College of Medicine), Rabi Hanna, Niketa C. Shah, Reema Kashif, Emily Limerick, Jordan Milner, Kimberly A. Kasow(University of North Carolina at Chapel Hill), Rakefet Shenkar, Ghada Abusin, Monica Bhatia(Columbia University Irving Medical Center), Eneida R. Nemecek(Oregon Health & Science University), Kris M. Mahadeo(Duke University), Mahvish Q. Rahim, Phavina A Akhom(Vanderbilt University Medical Center), Matthew M. Hsieh(National Institutes of Health), Michael J. Eckrich(Levine Children's Hospital), Gregory M.T. Guilcher(University of Calgary), Ashish O. Gupta(University of Minnesota), Christine Camacho-Bydume, Nahal Lalefar(University of California, San Francisco), J Stanek, Julie‐An Talano(Dana-Farber Cancer Institute), Biljana Horn(UF Health Shands Hospital), Shalini Shenoy(Washington University in St. Louis), Sonali Chaudhury(Lurie Children's Hospital), Julie Waldhart, Adetola Kassim(Vanderbilt University Medical Center), Lakshmanan Krishnamurti, Elizabeth O. Stenger, Yassine Khalid, Moshen Alzaharani, Carmem Bonfim, Timothy S. Olson, Luiz Guilherme Darrigo, John Horan, Akshay Sharma, Alexander Ngwube(Baylor College of Medicine), Kristin Page, Michael Kent, Christopher McKinney, Benjamin Philipson, Pooja Khandelwal, Robert Sheppard Nickel(Children's National)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310